메뉴 건너뛰기




Volumn 85, Issue 5, 2013, Pages 262-268

Sequential chemotherapies for advanced gastric cancer: A retrospective analysis of 111 patients

Author keywords

Gastric cancer; Second line chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

EID: 84886739501     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000355690     Document Type: Article
Times cited : (8)

References (29)
  • 2
    • 0027217474 scopus 로고
    • Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer
    • Murad AM, Santiago FF, Petroianu A, Rocha P, Rodrigues M, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
    • (1993) Cancer , vol.72 , pp. 37-41
    • Murad, A.M.1    Santiago, F.F.2    Petroianu, A.3    Rocha, P.4    Rodrigues, M.5    Rausch, M.6
  • 3
    • 0028959887 scopus 로고
    • Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
    • Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Brit J Cancer 1995; 71: 587-591.
    • (1995) Brit J Cancer , vol.71 , pp. 587-591
    • Pyrhönen, S.1    Kuitunen, T.2    Nyandoto, P.3    Kouri, M.4
  • 5
    • 26444529508 scopus 로고    scopus 로고
    • Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): Benefit dependent on progression-free interval after first-line therapy
    • Stahl M, Muller C, Koster W, Wilke H: Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy. Onkologie 2005; 28: 499-502.
    • (2005) Onkologie , vol.28 , pp. 499-502
    • Stahl, M.1    Muller, C.2    Koster, W.3    Wilke, H.4
  • 6
    • 14644421555 scopus 로고    scopus 로고
    • Review of secondline chemotherapy for advanced gastric adenocarcinoma
    • Wilson D, Hiller L, Geh JI: Review of secondline chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 2005; 17: 81-90.
    • (2005) Clin Oncol , vol.17 , pp. 81-90
    • Wilson, D.1    Hiller, L.2    Geh, J.I.3
  • 7
    • 0742271770 scopus 로고    scopus 로고
    • Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma
    • Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Normann AR: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64-69.
    • (2004) Ann Oncol , vol.15 , pp. 64-69
    • Assersohn, L.1    Brown, G.2    Cunningham, D.3    Ward, C.4    Oates, J.5    Waters, J.S.6    Hill, M.E.7    Normann, A.R.8
  • 9
    • 80053341349 scopus 로고    scopus 로고
    • Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    • Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314.
    • (2011) Eur J Cancer , vol.47 , pp. 2306-2314
    • Thuss-Patience, P.C.1    Kretzschmar, A.2    Bichev, D.3    Deist, T.4    Hinke, A.5    Breithaupt, K.6    Dogan, Y.7    Gebauer, B.8    Schumacher, G.9    Reichardt, P.10
  • 11
    • 0037263849 scopus 로고    scopus 로고
    • Gastric cancer epidemiology and risk factors
    • Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1-9.
    • (2003) J Clin Epidemiol , vol.56 , pp. 1-9
    • Kelley, J.R.1    Duggan, J.M.2
  • 12
    • 0037295092 scopus 로고    scopus 로고
    • Chemotherapy in gastric cancer: A never ending saga
    • Roth AD: Chemotherapy in gastric cancer: a never ending saga. Ann Oncol 2003; 14: 175-177.
    • (2003) Ann Oncol , vol.14 , pp. 175-177
    • Roth, A.D.1
  • 13
    • 0036015227 scopus 로고    scopus 로고
    • Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: Efficacy of therapy and value of serum tumor markers
    • Schulze-Bergkamen H, Zuna I, Teufel A, Stremmel W, Rudi J: Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers. Med Oncol 2002; 19: 43-53.
    • (2002) Med Oncol , vol.19 , pp. 43-53
    • Schulze-Bergkamen, H.1    Zuna, I.2    Teufel, A.3    Stremmel, W.4    Rudi, J.5
  • 14
    • 84859842052 scopus 로고    scopus 로고
    • Prognostic factors of second and third line chemotherapy using 5-FU with platinum, irinotecan, and taxane for advanced gastric cancer
    • Park JS, Lim JY, Park SK, Kim MK, Ko HS, Yoon SO, Kim JW, Choi SH, Cho JY: Prognostic factors of second and third line chemotherapy using 5-FU with platinum, irinotecan, and taxane for advanced gastric cancer. Cancer Res Treat 2011; 43: 236-243.
    • (2011) Cancer Res Treat , vol.43 , pp. 236-243
    • Park, J.S.1    Lim, J.Y.2    Park, S.K.3    Kim, M.K.4    Ko, H.S.5    Yoon, S.O.6    Kim, J.W.7    Choi, S.H.8    Cho, J.Y.9
  • 15
    • 77956262693 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
    • ToGA Trial Investigators
    • Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
    • (2010) Lancet , vol.376 , pp. 687-697
    • Bang, Y.J.1    Van Cutsem, E.2    Feyereislova, A.3    Chung, H.C.4    Shen, L.5    Sawaki, A.6    Lordick, F.7    Ohtsu, A.8    Omuro, Y.9    Satoh, T.10    Aprile, G.11    Kulikov, E.12    Hill, J.13    Lehle, M.14    Rüschoff, J.15    Kang, Y.K.16
  • 16
    • 0012234893 scopus 로고    scopus 로고
    • Randomized phase II study of weekly 24h infusion of high dose 5-FU +/-folinic acid (HD-FU +/-FA) vs. HD-FU/FA/ biweekly cisplatin in advanced gastric cancer
    • Vanhoefer U, Wagener T, Lutz M, Van Cutsem E, Nordlinger B, Reuse S, Baron B, Wilke H, Wils J: Randomized phase II study of weekly 24h infusion of high dose 5-FU +/-folinic acid (HD-FU +/-FA) vs. HD-FU/FA/ biweekly cisplatin in advanced gastric cancer. Eur J Cancer 2001; 37(suppl 6):S27.
    • (2001) Eur J Cancer , vol.37 , pp. S27
    • Vanhoefer, U.1    Wagener, T.2    Lutz, M.3    Van Cutsem, E.4    Nordlinger, B.5    Reuse, S.6    Baron, B.7    Wilke, H.8    Wils, J.9
  • 18
    • 0037090686 scopus 로고    scopus 로고
    • Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer
    • Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.
    • (2002) J Clin Oncol , vol.20 , pp. 1996-2004
    • Ross, P.1    Nicolson, M.2    Cunningham, D.3    Valle, J.4    Seymour, M.5    Harper, P.6    Price, T.7    Anderson, H.8    Iveson, T.9    Hickish, T.10    Lofts, F.11    Norman, A.12
  • 19
  • 20
    • 21644450088 scopus 로고    scopus 로고
    • Fluourouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first-line therapy for patients with advanced gastric cancer; First interim analysis of a randomised multicenter phase II study
    • Al-Batran S, Stöhlmacher J, Probst S, Hollerbach S, Wilhelm G, Derigs H, Seipelt G, Kojouharoff G, Graubner M, Hinke A, Jäger E: Fluourouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first-line therapy for patients with advanced gastric cancer; first interim analysis of a randomised multicenter phase II study. J Clin Oncol 2005; 23:S311.
    • (2005) J Clin Oncol , vol.23 , pp. S311
    • Al-Batran, S.1    Stöhlmacher, J.2    Probst, S.3    Hollerbach, S.4    Wilhelm, G.5    Derigs, H.6    Seipelt, G.7    Kojouharoff, G.8    Graubner, M.9    Hinke, A.10    Jäger, E.11
  • 21
    • 13244266683 scopus 로고    scopus 로고
    • Randomized multicenter phase II trial of biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803
    • Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C: Randomized multicenter phase II trial of biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-4328.
    • (2004) J Clin Oncol , vol.22 , pp. 4319-4328
    • Bouche, O.1    Raoul, J.L.2    Bonnetain, F.3    Giovannini, M.4    Etienne, P.L.5    Lledo, G.6    Arsene, D.7    Paitel, J.F.8    Guerin-Meyer, V.9    Mitry, E.10    Buecher, B.11    Kaminsky, M.C.12    Seitz, J.F.13    Rougier, P.14    Bedenne, L.15    Milan, C.16
  • 22
    • 22144469838 scopus 로고    scopus 로고
    • Randomized phase II evaluation of irinotecan plus high-dose 5-fluourouracil and leucovorin (IFL) versus 5-fluourouracil, leucovorin and etoposide (ELF) in untreated metastatic gastric cancer
    • Moehler M, Eimermacher A, Siebler J, Hohler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M: Randomized phase II evaluation of irinotecan plus high-dose 5-fluourouracil and leucovorin (IFL) versus 5-fluourouracil, leucovorin and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122-2128.
    • (2005) Br J Cancer , vol.92 , pp. 2122-2128
    • Moehler, M.1    Eimermacher, A.2    Siebler, J.3    Hohler, T.4    Wein, A.5    Menges, M.6    Flieger, D.7    Junginger, T.8    Geer, T.9    Gracien, E.10    Galle, P.R.11    Heike, M.12
  • 23
    • 32944474464 scopus 로고    scopus 로고
    • Randomized phase III trial of irinotecan (CPT 11)-5-FU/folinic acid (FA) vs. CDDP + 5-FU in first line advanced gastric cancer patients
    • Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, Goker E, Risse M, Awad L, Bugat R: Randomized phase III trial of irinotecan (CPT 11)-5-FU/folinic acid (FA) vs. CDDP + 5-FU in first line advanced gastric cancer patients. J Clin Oncol 2005; 23:S308.
    • (2005) J Clin Oncol , vol.23 , pp. S308
    • Dank, M.1    Zaluski, J.2    Barone, C.3    Valvere, V.4    Peschel, C.5    Wenczl, M.6    Goker, E.7    Risse, M.8    Awad, L.9    Bugat, R.10
  • 24
    • 33745547767 scopus 로고    scopus 로고
    • Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
    • Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
    • (2006) J Clin Oncol , vol.24 , pp. 2903-2909
    • Wagner, A.D.1    Grothe, W.2    Haerting, J.3    Kleber, G.4    Grothey, A.5    Fleig, W.E.6
  • 25
    • 2142703727 scopus 로고    scopus 로고
    • Survival of patients with advanced colorectal cancer improves with the availability of fluourouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment
    • Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluourouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
    • (2004) J Clin Oncol , vol.22 , pp. 1209-1214
    • Grothey, A.1    Sargent, D.2    Goldberg, R.M.3    Schmoll, H.J.4
  • 27
    • 80052246962 scopus 로고    scopus 로고
    • Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer
    • Bohanes P, Courvoisier DS, Perneger TV, Morel P, Huber O, Roth AD: Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer. Swiss Med Wkly 2011; 141:w13249.
    • (2011) Swiss Med Wkly , vol.141 , pp. w13249
    • Bohanes, P.1    Courvoisier, D.S.2    Perneger, T.V.3    Morel, P.4    Huber, O.5    Roth, A.D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.